Large Practices Might Evolve Into ACOs
Large Practices Might Evolve Into ACOs
MANAGED CARE June 2010. ©MediMedia USA
Researchers at the Dartmouth Institute for Health Policy and Clinical Practice argue that large medical groups could be well positioned to serve as accountable care organizations (ACOs), according to an article in Health Affairs.
ACOs are provider-led, local health care delivery systems that would accept responsibility for the continuum of care for their primary care patients and have financial incentives to improve quality and reduce the costs of care.
The researchers examined the cost and quality of care delivered to fee-for-service Medicare beneficiaries in 22 markets by physicians in small group practices and in large multispecialty groups. All were members of the Council for Accountable Physician Practices (CAPP), an affiliate of the American Medical Group Association.
Overall, the large multispecialty group practices improved the quality of care by 5 percent to 15 percent at a 3.6 percent ($272) lower annual cost per patient, compared to the smaller group practices. The researchers point out that existing integrated delivery systems, multispecialty group practices, hospitals that employ their own primary care physicians, and well-established physician networks (such as some independent practice associations) are already structured in ways that would allow them to participate as ACOs. Mechanisms to help small practices establish integrated networks could be developed, allowing these smaller groups to have similar advantages.
Our other journal
P&T Journal for November 2014
Features

LETTER TO THE EDITOR
Medications for Parkinson’s Disease
PERSPECTIVE
The Changing Roles of P&T Committees
Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies
PIPELINE PLUS
Modest Growth Seen in Epilepsy Market
MEETING HIGHLIGHTS
European Society of Cardiology and Transcatheter Cardiovascular Therapeutics
BOOK REVIEW
“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD
DEPARTMENTSMEDICATION ERRORS
Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment
PRESCRIPTION: WASHINGTON
FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds
New Drugs/Drug News
Pharmaceutical Approval Update
DRUG FORECAST
Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension